Zepbound trials in adults with obesity or overweight
Row in the source: Hair loss
Placebo1%On Zepbound (by dose)4% to 5%
Who was studied
Adults with obesity or overweight in 2 trials. One trial included only people with type 2 diabetes; the other left them out. 2,519 got Zepbound in three dose groups and 958 got placebo.
These lines are copied from our side effect pages, word for word.
Zepbound: Hair loss
The Zepbound label links hair loss to weight loss. In the weight trials, 7.1% of women and 0.5% of men on Zepbound reported hair loss. On placebo, 1.3% of women and no men did. No one stopped Zepbound because of hair loss.
Wegovy HD is a higher weekly dose. Two 72-week trials compared it with the usual Wegovy dose and with placebo. Nausea was reported by 39% on Wegovy HD, 35% on the usual dose, and 13% on placebo.
Changes in skin feeling, such as tingling, burning, or sensitive skin, were reported by 22%, 6%, and under 1%. Among people on Wegovy HD who had these skin changes, 18% did not report recovering during the trial. Hair loss was reported by 6%, 3%, and 1%.
Every number is copied from a table on our side effect pages. Those tables come from FDA labels on DailyMed, results posted on ClinicalTrials.gov, and company trial results. We did not add, total, or rank any number. Rows keep one fixed order: FDA-approved medicines first, then the rest, each in A to Z order.
We group rows by name. For example, “Tiredness (fatigue)” and “Tiredness or weakness (fatigue)” are both under tiredness. Each row still shows its own words from the source.
The tables on this site copy part of each label, such as the most common problems. A problem missing from one table may still have happened.